UNAIDS - 2 October 2009

The promise of a vaccine against HIV has got one step closer. Results from the largest vaccine trial ever conducted show a modest but encouraging 31% efficacy in preventing new HIV infections in Thailand. This has vindicated thousands of scientists and volunteers who have been hoping that a safe and highly effective HIV vaccine is possible.

This news comes at a time when the movement to achieve universal access to HIV prevention and treatment is gaining momentum. Today more than 4 million people living with HIV are receiving antiretroviral treatment and fewer babies are being born with HIV. With less than half the people who need treatment having access and with each day more people becoming infected with HIV than are started on treatment, we are mortgaging our future. But we are also exposing a fundamental social injustice--between the privileged and the forsaken--a divide we can bridge.

An acceptable vaccine is not yet ready, but let us prepare today for tomorrow. Let us learn from the lessons of the AIDS response thus far.

The first challenge is access and affordability. Antiretroviral treatment has been around since 1996, but real access to treatment began only when public pressure was put on world leaders and the prices of medicines came down. Today, AIDS activists are repeating these efforts to reduce prices, this time for second line antiretroviral medicines. It is unacceptable that 98% of pregnant women in developed countries are able to access HIV prophylaxis to stop transmission to their babies when little more than 33% in developing countries can do so.

The news coincides with this week's United Nations General Assembly. During which the Secretary-General reminded us of "our commitment to equity" and where I appealed to many Heads of State who are committed to promoting equity to place equity in the AIDS response high on their list. We must not allow cost to deter people from access to a vaccine.

The second challenge is creating the conditions for massive uptake of an effective vaccine. Time and again, women and girls are unable to make independent decisions about their health and education. Many men and women do not come forward to take an HIV test for fear of stigma and discrimination. People without a voice--sex workers and their clients, injecting drug users and men who have sex with men--are often excluded from health and social welfare programmes. We look to civil society to continue to break down the barriers to vaccine uptake.

The third challenge is in creating health systems capable of delivering the vaccine. Currently clinics are geared towards immunizing infants and young children. The largest benefits of an HIV vaccine will likely accrue from vaccinating the present cohort of young people and those at higher risk of HIV exposure. A failure to reach adolescents will represent another failure to break the back of the epidemic.

There is no time for complacency in our efforts to stop new HIV infections. The world needs a strong HIV prevention campaign that is evidence-informed and grounded in human rights. It is high time to end discrimination, bad laws, and harmful social norms that fuel HIV transmission.

As scientists and world leaders absorb the implications of the Thai study results in the coming weeks they must be mindful of these challenges. A "ready to use" vaccine is years--perhaps decades away, but when it does become available, it ought to be financed as a public good that is accessible for all. How else can we reasonably expect to put an end to this epidemic?

Resources:

Press centre:

Largest ever HIV vaccine trial results are very encouraging (24 September 2009) - http://www.aegis.org/news/unaids/2009/UN090917.html

Publications:

Making HIV trials work for women and adolescent girls (July 2008) (pdf, 140 Kb.) - http://data.unaids.org/pub/BrochurePamphlet/2008/JC1605_hiv_trial s_brochure_en.pdf

Ethical considerations in biomedical HIV prevention trials (pdf, 750 Kb.) - http://data.unaids.org/pub/Manual/2007/jc1349_ethics_2_11_07_en.p df

Good participatory practice guidelines for biomedical HIV prevention trials (pdf, 3.04 Mb.) - http://data.unaids.org/pub/Manual/2007/jc1364_good_participatory_ guidelines_en.pdf
091002
UN091001

Copyright © 2009 - Joint United Nations Programme on HIV/AIDS (UNAIDS). All rights reserved. UNAIDS articles, which are not formal publications of UNAIDS, may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The documents may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .